title: Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
abstract: There are few data on clinical and virological factors associated with maraviroc virological response (VR) in clinical practice. This study aimed to identify factors associated with VR in 94 treatment-experienced, but CCR5 inhibitor-naive, HIV-1 patients switched to maraviroc-containing regimens.
  
  
  
  Patients with HIV-1 RNA viral load (VL) <50 copies/mL switching to an antiretroviral treatment containing maraviroc were followed. VR was defined at month 3 as VL <50 copies/mL. The impact of age, baseline tropism, zenith VL, nadir CD4 cell count and CD4 cell count, HIV subtype (B versus non-B), genotypic susceptibility score of treatment, once- or twice-daily treatment and presence of raltegravir in optimized background therapy on VR was investigated.
  
  
  
  Baseline characteristics were: median age 49 years (range 25-73 years), median CD4 cell count 481 cells/mm(3) (range 57-1830 cells/mm(3)) and median nadir CD4 cell count 99 cells/mm(3) (range 3-585). Maraviroc was administered twice daily in 88 of 94 patients and once daily in 6 of 94 patients (300 mg/day for 4 of 6 and 150 mg/day for 2 of 6). At month 3, 89.4% of patients were responders. A better VR to a switch regimen containing maraviroc was associated with the B subtype (P = 0.0216) and a lower zenith VL (median of 5.24 and 5.70 log10 copies/mL for patients in success or in failure, respectively) in univariate analysis. Only B subtype was associated with a better VR in multivariate analysis.
  
  
  
  This study evidenced the efficacy of a switch regimen containing maraviroc in clinical practice. VR was better for patients with a lower zenith VL and B subtype.
authors.affiliation: Virology Laboratory CHRU, Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Bocket
authors.affiliation: Pharmacology Laboratory Bichat Hospital APHP, Paris, France IAME, UMR 1137-Université Paris Diderot, Sorbonne Paris Cité, France INSERM UMR 1137, F-75018 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
authors.affiliation: Virology Laboratory CHRU, Lille, France.
authors.forename: E K
authors.initials: EK
authors.lastname: Alidjinou
authors.affiliation: Infectious Diseases Department Dron Hospital, Tourcoing, France.
authors.forename: F
authors.initials: F
authors.lastname: Ajana
authors.affiliation: Infectious Diseases Department Dron Hospital, Tourcoing, France.
authors.forename: P
authors.initials: P
authors.lastname: Choisy
authors.affiliation: Pharmacology Laboratory Bichat Hospital APHP, Paris, France IAME, UMR 1137-Université Paris Diderot, Sorbonne Paris Cité, France INSERM UMR 1137, F-75018 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Lê
authors.affiliation: IAME, UMR 1137-Université Paris Diderot, Sorbonne Paris Cité, France INSERM UMR 1137, F-75018 Paris, France AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Charpentier
authors.affiliation: IAME, UMR 1137-Université Paris Diderot, Sorbonne Paris Cité, France INSERM UMR 1137, F-75018 Paris, France AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Descamps
authors.affiliation: Infectious Diseases Department Bichat Hospital, Paris, France.
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75005 Paris, France INSERM-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75013 Paris, France Infectious Diseases Department Pitié Salpêtrière Hospital, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.affiliation: Internal Medicine Department Pitié Salpêtrière Hospital, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Simon
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75005 Paris, France INSERM-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75013 Paris, France AP-HP, Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Virologie, Paris F-75013, France.
authors.forename: V
authors.initials: V
authors.lastname: Calvez
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75005 Paris, France INSERM-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75013 Paris, France AP-HP, Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Virologie, Paris F-75013, France.
authors.forename: A-G
authors.initials: AG
authors.lastname: Marcelin
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75005 Paris, France INSERM-UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, F-75013 Paris, France AP-HP, Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Virologie, Paris F-75013, France cathia.soulie@psl.aphp.fr.
authors.forename: C
authors.initials: C
authors.lastname: Soulie
mesh_terms: D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D065100:CCR5 Receptor Antagonists / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc